Desmoid tumor: cross-border specialty drug access for international patients

Quick orientation

Desmoid tumors are rare locally-aggressive soft-tissue neoplasms with an incidence of approximately 2 to 4 cases per million people per year. They are sometimes associated with familial adenomatous polyposis.

Typical age of onset. Most commonly diagnosed between ages 15 and 60, with a peak in young adults. Female predominance is reported.

Severity tiers. Desmoid tumors do not metastasize but can cause significant local morbidity through invasion of adjacent structures. Some regress spontaneously; others progress relentlessly.

Why specialty drugs for Desmoid tumor are hard to access internationally

Ogsiveo (nirogacestat), approved by the FDA in 2023, is the first targeted therapy specifically labeled for desmoid tumors. International registration is in early stages. Off-label tyrosine kinase inhibitors have been used historically; access to nirogacestat internationally is largely cross-border.

Treatments approved by the FDA

• Ogsiveo (nirogacestat) — FDA approval: 2023. Mechanism: Gamma-secretase inhibitor. Route: Oral twice daily. US WAC ballpark: Approximately USD 240,000 per year. Country pricing: Saudi Arabia · Egypt.

Cross-border pathways used for Desmoid tumor

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

• Named Patient Program (NPP)
• Expanded Access Program (EAP)
• Compassionate Use
• Personal Import Scheme

What your physician needs to know

• Confirm desmoid diagnosis by biopsy with CTNNB1 or APC genotyping where appropriate.
• Document progression on imaging that warrants systemic therapy versus active surveillance.
• Monitor ovarian function; nirogacestat carries a risk of ovarian toxicity.
• Screen for skin and gastrointestinal adverse events.
• Coordinate with sarcoma oncology or hereditary cancer team where FAP is present.

Common questions

Is active surveillance still appropriate?

Many desmoid tumors regress or stabilize spontaneously. Active surveillance remains the first option for non-progressive disease.

Is Ogsiveo approved outside the US?

International registration is in early stages. We confirm by destination.

What are the main side effects?

Diarrhea, ovarian toxicity, skin and hair changes, and electrolyte shifts are common in trials. Your oncologist counsels on monitoring.

How long is treatment?

Treatment continues as long as benefit is observed and tolerability allows. There is no fixed course.

What documents are required?

Oncologist's prescription, pathology report, recent imaging, and clinical summary.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Desmoid tumor, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Desmoid tumor

Reserved for you.